Pharma BD Deal Intelligence
A modest dermatology tuck-in whose pipeline candidates died on the vine and whose fate was overtaken within a year by Stiefel's own $2.9B sale to GSK
Full analysis, sources & comparables →The $4.15 per share price represents a premium of approximately 73% to Barrier Therapeutics' average closing price... 'We believe that this transaction…
Stiefel's $4.15/share offer for Barrier represented a 135% premium over prior close, bringing three marketed dermatology products and five clinical candidates…
Stiefel completed the tender offer for Barrier Therapeutics on August 6, 2008, closing the ~$148M dermatology consolidation that united Xolegel, Vusion and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Stiefel Laboratories acquired Barrier Therapeutics for approximately $148 million via an all-cash tender offer at $4.15 per share, a roughly 48-73% premium depending on the reference period. The deal brought Barrier's marketed dermatology products (including Xolegel, Vusion, and Solage) and a pipeline of clinical candidates into Stiefel's existing dermatology franchise; the transaction closed August 6, 2008 after HSR clearance.
A modest dermatology tuck-in whose pipeline candidates died on the vine and whose fate was overtaken within a year by Stiefel's own $2.9B sale to GSK
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Stiefel Laboratories / Barrier Therapeutics, Inc. (this deal) | 2008 | $148M | 37 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| LEO Pharma A/S / AstraZeneca PLC | 2016 | $1.1B | 80 |
← Browse all deals · How we score deals
More: 2008 deals · Dermatology deals